ClinicalTrials.gg
Not yet recruitingNCT07434024ESP-BACKUpdated Mar 17, 2026

Erector Spinae Plane Block for Acute Low Back Pain

An interventional study of Erector Spinae Plane Block with isotonic saline and Erector Spinae Plane Block with local anesthetic in Non-specific Low Back Pain (NSLBP), sponsored by University Hospital, Montpellier. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Low Back Pain by University Hospital, Montpellier — 3 open to participants now, 4 under way, 1 of them phase 3. Low Back Pain · University Hospital, Montpellier.

Started
2026
with 1 other
No phase
6 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Low Back Pain by University Hospital, Montpellier, this one is one of 2 that started in 2026, is one of 6 with no phase, and was the 10th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

3 of the 10 studies in Low Back Pain by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Low Back Pain by University Hospital, Montpellier, or all of them as a file.
02

Study summary

Non-Specific low back pain (NSLB) is an important public health problem with a major economic and social impact. It is defined by the location of pain, between the lower rib margins and the lumbar vertebrae. Medical management of Non-Specific low back pain injury focuses on reducing pain and its consequences. Nowadays, no strategy has shown optimal effectiveness to improve outcome substantially. The ultrasound-guided erector spinae plane block (ESPB) is a well-known intermuscular compartment block. In the absence of red flag signs, ESPB can be performed for low back pain to reduce pain, decrease opiate requirements and limit emergency admissions for refractory pain. This study aims to evaluate the impact of the ESPB in patients suffering from NSLB.

Read the detailed description

The study is a multicenter randomized clinical trial. The patients are recruited on the day of admission in the emergency department for Non-Specific low back pain.They are randomly assigned to receive either regional anesthesia with a local anesthetic (ESP BLOCK Group) or placebo (CONTROL Group). The primary objective is to evaluate whether the ESPB is an effective treatment for patients with NSLB pain, by reducing pain and allowing immediate mobility. The secondary objectives of this study are multidimensional and aim to compare patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs), as well as clinical and economic outcomes, over a six-month follow-up period.

03

Conditions studied

  • Non-specific Low Back Pain (NSLBP)

Browse trials for

Keywords

  • Non-Specific low back pain ;
  • Erector Spinae Plane Block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult (≥ 18 years);
  • Non-specific low back pain (≤ 5 days);
  • Pain score (VAS) ≥ 5 (during mobilization);
  • Inability to walk easily (failure of the "Get Up and Go" test in less than 20 seconds).

Exclusion criteria

Exclusion Criteria:

  • Low back pain of known specific origin: spine surgery, spine trauma, discal hernia, facet joint, radicular (sciatica, cruralgia, meralgia paresthetica), muscle pain, cancer-related or rheumatological disease;
  • Referred or chronic pain;
  • Patients with opioids (acute or chronic pain and/or misuse);
  • to regional anaesthesia;
  • Contraindication to ropivacaine, dexamethasone, sodium chloride, NSAID, paracetamol, tramadol;
  • Known to ropivacaine, dexamethasone, other amide-type local anesthetics, or any of the ;
  • Addiction to drugs, alcohol or medication;
  • Patients with anticoagulants for a curative use (not preventive);
  • Patients with cancer or risk of bone or; severe osteoporosis;
  • Acute inflammatory diseases (e.g., rheumatoid arthritis, ankylosing spondylitis…);
  • Patient with severe hypotension or uncontrolled hypertension or; Heart Block (uncorrected second- or third-degree heart block without a pacemaker) or; severe bradycardia;
  • Patients with severe liver or renal disease or peptic ulcer disease;
  • Presence of infection or sepsis at the injection site;
  • Patients with uncontrolled bacterial, viral, or protozoan infections or; systemic fungal infections or; active untreated tuberculosis or; active ocular herpes simplex infections;
  • Patients with uncontrolled diabetes mellitus;
  • Patients with glaucoma or history of severe glaucoma;
  • Patients with severe psychiatric conditions;
  • Subject unable to read or/and write (inability to complete a self-administered questionnaire);
  • Unavailability for follow up during 6 months;
  • Participation in another clinical trial involving an medicinal product or medical device within 4 weeks preceding the screening date;
  • Pregnancy in progress or planned during the study period or breastfeeding women (Art. L1121-5 of the French Public Health Code);
  • Women of (WOCBP) without a negative of highly sensitive pregnancy test before inclusion or not using a highly effective method of ;
  • Patients protected by law (Art. L1121-6 and L1121-8 of the French Public Health Code): Individuals deprived of their liberty by judicial or administrative decision, minors, adults under law protection or unable to express their consent or patient under guardianship or curatorship;
  • Patients not covered by a French social security scheme or not benefiting from such a scheme;
  • Absence of signed form before inclusion from the patient;
  • Patient already included in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Experimental group (ESPB)

    A single injection will be performed at the erector spinae plane site, 20 ml of ropivacaine 0.2% then 8 mg of dexamethasone (2 ml) will be administered sequentially through the same needle using two separate syringes in order to prevent the risk of precipitation between the two solutions. The injection will be performed unilaterally or bilaterally as per the randomization stratification

    Procedure: Erector Spinae Plane Block with local anesthetic

  • Placebo comparator
    Control group (placebo)

    A single injection of 22 ml isotonic saline solution will be performed at the same anatomical site as the experimental group. To maintain the double-blind design, the saline solution will be administered sequentially through the same needle using two separate syringes (20 mL + 2 mL). The injection will also be performed unilaterally or bilaterally, according to the randomization stratification.

    Procedure: Erector Spinae Plane Block with isotonic saline

Interventions

  • ProcedureErector Spinae Plane Block with isotonic saline

    Ultrasound-guided erector spinae plane block performed under aseptic conditions by an experienced physician, consisting of an interfascial injection in the erector spinae plane using an isotonic saline solution.

  • ProcedureErector Spinae Plane Block with local anesthetic

    Ultrasound-guided erector spinae plane block performed under aseptic conditions by an experienced physician, consisting of an interfascial injection in the erector spinae plane using a local anesthetic solution.

06

What researchers measure

Primary outcomes

  1. Rate of Success of the treatment

    The primary endpoint is the success of the treatment before hospital discharge defined by a composite criteria combining the reduction of pain on mobilization (50% decrease in pain intensity) and the validation of the "Get up and go" test (in less than 20 seconds).

    Time frame: 30 minutes post-procedure

Secondary outcomes

  1. VAS Pain assessments

    The Visual Analog Scale (VAS) will provide a subjective evaluation of pain severity by the patient on a scale ranging from 0 to 10, where 0 signifies no pain and 10 represents the most intense pain imaginable. This measurement is essential for capturing the patient's own perception of pain following the intervention.

    Time frame: The day of procedure up to 6 months

  2. Brief Pain Inventory (BPI) pain scores

    The Brief Pain Inventory (BPI) questionnaire serves as a comprehensive tool for assessing the severity of pain and its impact on various aspects of daily life. By capturing detailed information about pain experiences, including its intensity, interference with daily activities, and emotional impact, the BPI facilitates a nuanced understanding of the patient's pain experience. The BPI includes 2 subdimensions (pain severity and pain interference) range from 0 (no pain or no interference) to 10 (worst imaginable pain / complete interference)

    Time frame: on day 14, month 3, and month 6

  3. Consumption of rescue analgesics

    Consumption of rescue analgesic (total number of tablets of tramadol)

    Time frame: The day of procedure up to 6 months

  4. Steps counts

    Activity levels will be continuously monitored for 3 days using smartwatch technology. Metrics such as the number of steps taken will be recorded.

    Time frame: The day of procedure up to 3 days

  5. Quality of sleep

    Sleep duration will be continuously monitored for 3 days using smartwatch technology.

    Time frame: The day of procedure up to day 3

  6. EIFEL score

    The EIFEL questionnaireis a 24-item self-administered questionnaire, adapted from the Roland and Morris Disability Questionnaire, used to assess the functional impact of low back pain. For each of the 24 statements, the patient must tick the box if the statement corresponds to their current situation. If the patient is bedridden due to back pain, they must tick the specific box provided before the 24 statements and stop completing the questionnaire. The total score is calculated by summing the number of boxes ticked. A higher total score reflects a greater functional impairment related to low back pain

    Time frame: on day 3

  7. WOMAC scores

    The WOMAC questionnaire is a self-administered questionnaire consisting of 24 items divided into three subscales: pain (5 items), stiffness (2 items) and physical Function (17 items). Each item is scored from 0 to 4, yielding a total score ranging from 0 (no disability) to 96 (severe disability). The WOMAC provides valuable insights into the patient's pain levels, stiffness, physical function, and overall impact on daily living.

    Time frame: on day 14, month 3, and month 6

  8. Quality of life SF12 Scores

    The SF12 questionnaire is a self-reported outcome measure assessing the impact of health on an individual's everyday life. Patients fill out a 12-question survey across multiple domains covering physical and mental health. Two summary measures will be obtained: the Physical Component Summary (PCS) and the Mental Component Summary (MCS) range from 0 (worst) to 100 (best) quality of life.

    Time frame: at month 3 and month 6

  9. Health-related quality of life Scores

    The EQ-5D-5L is a questionnaire used to measure a person's health-related quality of life. It includes five dimensions-mobility, self-care, usual activities, pain/discomfort, and anxiety/depression-each rated on five levels of severity. The responses form a code that describes the person's health state. It also includes a visual analogue scale (VAS) where individuals rate their overall health on a scale from 0 (worst) to 100 (best)

    Time frame: The day of procedure and at 6 month

  10. Opioid misuse

    The POMI questionnaire is a 6-item self-administered questionnaire designed to detect opioid misuse behaviour. Each YES answer is counted as 1 point and each NO answer is counted as 0 points. A score of 2 points or more indicates an opioid use disorder

    Time frame: on day 14, month 3, and month 6

  11. Time to return to work

    Tracking the time taken for patients to return to work following treatment provides valuable insights into functional recovery and rehabilitation outcomes

    Time frame: at month 6

  12. Number of physiotherapy sessions

    The Number of physiotherapy sessions for low back pain willbe recorded

    Time frame: At month 6

  13. Number of recurrences

    Number of recurrences of low back pain willbe recorded

    Time frame: at month 6

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Mar 2029, 36 months later.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 36 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 25, 2026
StartEst.
Mar 2026
Primary completionEst.
Mar 2029
CompletionEst.
Jan 2030
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07434024
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Mar 2026 (estimated)
Primary completion
Mar 2029 (estimated)
Completion
Jan 2030 (estimated)
Last update
Mar 17, 2026

Study contacts

Sophie Bringuier, Pharm D PhD
Contact
s-bringuierbranchereau@chu-montpellier.fr
+33467338661
Xavier Cadevila, MD PHD
Contact
x-capdevila@chu-montpellier.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion